On Friday, Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) was -13.54% drop from the session before settling in for the closing price of $4.58. A 52-week range for IRWD has been $3.06 – $15.70.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 1.05% over the last five years. When this article was written, the company’s average yearly earnings per share was at 101.55%. With a float of $155.77 million, this company’s outstanding shares have now reached $160.02 million.
The firm has a total of 267 workers. Let’s measure their productivity. In terms of profitability, gross margin is 99.6%, operating margin of 28.68%, and the pretax margin is 18.91%.
Ironwood Pharmaceuticals Inc (IRWD) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Ironwood Pharmaceuticals Inc stocks. The insider ownership of Ironwood Pharmaceuticals Inc is 2.66%, while institutional ownership is 103.14%. The most recent insider transaction that took place on Dec 27 ’24, was worth 241,736. Before that another transaction happened on Nov 18 ’24, when Company’s SVP, Chief Business Officer sold 5,360 for $4.08, making the entire transaction worth $21,869. This insider now owns 284,685 shares in total.
Ironwood Pharmaceuticals Inc (IRWD) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 101.55% per share during the next fiscal year.
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Trading Performance Indicators
You can see what Ironwood Pharmaceuticals Inc (IRWD) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.62. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.67. Likewise, its price to free cash flow for the trailing twelve months is 5.12.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.02, a number that is poised to hit 0.06 in the next quarter and is forecasted to reach 0.25 in one year’s time.
Technical Analysis of Ironwood Pharmaceuticals Inc (IRWD)
Analysing the last 5-days average volume posted by the [Ironwood Pharmaceuticals Inc, IRWD], we can find that recorded value of 2.55 million was better than the volume posted last year of 2.41 million. As of the previous 9 days, the stock’s Stochastic %D was 44.75%. Additionally, its Average True Range was 0.37.
During the past 100 days, Ironwood Pharmaceuticals Inc’s (IRWD) raw stochastic average was set at 41.96%, which indicates a significant increase from 33.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 100.62% in the past 14 days, which was higher than the 78.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.04, while its 200-day Moving Average is $5.51. Now, the first resistance to watch is $4.41. This is followed by the second major resistance level at $4.87. The third major resistance level sits at $5.10. If the price goes on to break the first support level at $3.73, it is likely to go to the next support level at $3.50. Now, if the price goes above the second support level, the third support stands at $3.04.
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Key Stats
There are 160,028K outstanding shares of the company, which has a market capitalization of 633.71 million. As of now, sales total 442,740 K while income totals -1,002 M. Its latest quarter income was 91,590 K while its last quarter net income were 3,650 K.
